Catherine Smith, MD

Title(s)Associate Professor, Medicine
SchoolSchool of Medicine
Address513 Parnassus Ave, HSE, #713
San Francisco CA 94143
ORCID ORCID Icon0000-0003-0160-7026 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Duke University, Durham, NCM.D.05/2002School of Medicine
    Yale University, New Haven, CTB.S.05/1998Chemistry
    Collapse Awards and Honors
    American Association of Cancer Research20152015 Next Gen Star Award
    European Hematology Association/American Society of Hematology2010Translational Research Training Program Award
    Leukemia and Lymphoma Society 2010  - 2013Special Fellow in Clinical Research Career Development Award
    Duke University School of Medicine2002American Medical Women’s Association, Inc. Janet M. Glasgow Memorial Achievement Citation
    Duke University School of Medicine2002E. E. Owen, M.D. Clinical Scholar Award
    Duke University School of Medicine2001Alpha Omega Alpha
    Duke University School of Medicine2001William G. Anylan Scholarship
    Yale University1998Cum Laude
    Yale University1998Howard Douglass Moore Prize in Chemistry
    Yale University1998Michael T. Manzella Award

    Collapse Overview 
    Collapse Overview
    My laboratory focuses on identification of therapeutic resistance mechanisms and novel treatment strategies for acute myeloid leukemia (AML). We have a particular emphasis on AML associated with mutations in Fms-like Tyrosine Kinase-3 (FLT3). FLT3 is mutated in ~30% of AML, with constitutively activating FLT3 internal tandem duplication (ITD) mutations conferring a poor prognosis. We employ a prototypical “bedside to bench and back” approach to the problem of cancer drug resistance, founded on the belief that the ultimate pathway to improved cancer therapy begins with translational studies that utilize samples from patients who have undergone therapy in real time. This strategy allows us to interrogate how tumors can evolve under the selective pressure of cancer therapy and allows us to devise ways to circumvent these evolutionary adaptations.
    Collapse In The News

    Collapse Research 
    Collapse Research Activities and Funding
    RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation
    NIH/NCI 1R01CA266422-01A1Jul 1, 2022 - Jun 30, 2027
    Role: PI
    Investigating Resistance to FLT3 Inhibitors in AML
    NIH K08CA187577Sep 1, 2014 - Aug 31, 2018
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Structural surfaceomics reveals an AML-specific conformation of integrin ß2 as a CAR T cellular therapy target. Nat Cancer. 2023 Oct 30. Mandal K, Wicaksono G, Yu C, Adams JJ, Hoopmann MR, Temple WC, Izgutdina A, Escobar BP, Gorelik M, Ihling CH, Nix MA, Naik A, Xie WH, Hübner J, Rollins LA, Reid SM, Ramos E, Kasap C, Steri V, Serrano JAC, Salangsang F, Phojanakong P, McMillan M, Gavallos V, Leavitt AD, Logan AC, Rooney CM, Eyquem J, Sinz A, Huang BJ, Stieglitz E, Smith CC, Moritz RL, Sidhu SS, Huang L, Wiita AP. PMID: 37904046.
      View in: PubMed   Mentions:    Fields:    
    2. The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib. Am J Hematol. 2023 Oct 10. Joshi SK, Pittsenbarger J, Kennedy VE, Peretz CAC, Perl AE, Smith CC, Tyner JW, Druker BJ, Traer E. PMID: 37815132.
      View in: PubMed   Mentions:    Fields:    
    3. Association of geriatric measures and global frailty with cognitive decline after allogeneic hematopoietic cell transplantation in older adults. J Geriatr Oncol. 2023 Sep 05; 14(8):101623. Huang LW, Shi Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Boscardin WJ, Steinman MA, Olin RL. PMID: 37678052.
      View in: PubMed   Mentions:    Fields:    
    4. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. Lancet Haematol. 2023 Sep; 10(9):e767-e776. Shallis RM, Daver N, Altman JK, Komrokji RS, Pollyea DA, Badar T, Bewersdorf JP, Bhatt VR, de Botton S, de la Fuente Burguera A, Carraway HE, Desai P, Dillon R, Duployez N, El Chaer F, Fathi AT, Freeman SD, Gojo I, Grunwald MR, Jonas BA, Konopleva M, Lin TL, Mannis GN, Mascarenhas J, Michaelis LC, Mims AS, Montesinos P, Pozdnyakova O, Pratz KW, Schuh AC, Sekeres MA, Smith CC, Stahl M, Subklewe M, Uy GL, Voso MT, Walter RB, Wang ES, Zeidner JF, Žucenka A, Zeidan AM. PMID: 37572683.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML). Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):tps7077-tps7077. Smith SC, Vachhani VP, Garcia-Manero GG, Grieselhuber GN, Guru Murthy GG, Bhatia BA, Arora AJ, Izadi IH, Fiorino FA, Rampal RR. .
      View in: Publisher Site   Mentions:
    6. Multiomic Single Cell Sequencing Identifies Stemlike Nature of Mixed Phenotype Acute Leukemia and Provides Novel Risk Stratification. bioRxiv. 2023 May 18. Peretz CAC, Kennedy VE, Walia A, Delley CL, Koh A, Tran E, Clark IC, Hayford CE, D'Amato C, Xue Y, Fontanez KM, Roy R, Logan AC, Perl AE, Abate A, Olshen A, Smith CC. PMID: 37292835; PMCID: PMC10245585.
      View in: PubMed   Mentions:
    7. Microfluidics-free single-cell genomics with templated emulsification. Nat Biotechnol. 2023 Nov; 41(11):1557-1566. Clark IC, Fontanez KM, Meltzer RH, Xue Y, Hayford C, May-Zhang A, D'Amato C, Osman A, Zhang JQ, Hettige P, Ishibashi JSA, Delley CL, Weisgerber DW, Replogle JM, Jost M, Phong KT, Kennedy VE, Peretz CAC, Kim EA, Song S, Karlon W, Weissman JS, Smith CC, Gartner ZJ, Abate AR. PMID: 36879006.
      View in: PubMed   Mentions: 9     Fields:    
    8. 304 HLA-DPB1 Mismatch Permissiveness and Activating KIR Haplotypes Have Different Impact on Allogeneic Hematopoietic Cell Transplant Survival Outcomes in Acute Leukemias and Myelodysplastic Syndrome. Transplantation and Cellular Therapy. 2023 Feb 1; 29(2):s232-s233. Lee LJ, Rajalingam RR, Kong KD, Ai AW, Andreadis AC, Damon DL, Dunavin DN, Gaensler GK, Kaplan KL, Martin MT, Olin OR, Sayre SP, Smith SC, Wolf WJ, Logan LA. .
      View in: Publisher Site   Mentions:
    9. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. J Clin Oncol. 2022 12 10; 40(35):4048-4059. Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK. PMID: 35849791; PMCID: PMC9746764.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    10. Abstract LB516A: The irreversible FLT3 inhibitor FF-10101 is active against a diversity of FLT3 inhibitor resistance mechanisms. Cancer Research. 2022 Jun 15; 82(12_Supplement):lb516a-lb516a. Ferng FT, Terada TD, Ando AM, Tarver TT, Chaudhary CF, Lin LK, Logan LA, Smith SC. .
      View in: Publisher Site   Mentions:
    11. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood Cancer J. 2022 05 30; 12(5):84. Perl AE, Hosono N, Montesinos P, Podoltsev N, Martinelli G, Panoskaltsis N, Recher C, Smith CC, Levis MJ, Strickland S, Röllig C, Groß-Langenhoff M, Chou WC, Lee JH, Yokoyama H, Hasabou N, Lu Q, Tiu RV, Altman JK. PMID: 35637252; PMCID: PMC9151663.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    12. The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms. Mol Cancer Ther. 2022 05 04; 21(5):844-854. Ferng TT, Terada D, Ando M, Tarver TC, Chaudhary F, Lin KC, Logan AC, Smith CC. PMID: 35395091; PMCID: PMC9081245.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    13. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022 04 12; 6(7):2144-2155. Smith CC, Levis MJ, Perl AE, Hill JE, Rosales M, Bahceci E. PMID: 35130342; PMCID: PMC9006281.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    14. Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplant Cell Ther. 2022 06; 28(6):309.e1-309.e9. Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Huang CY, Olin RL. PMID: 35247612; PMCID: PMC9198006.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. RNA Polymerase II Is a Therapeutic Target to Overcome FLT3 Inhibitor Resistance Mediated By the Bone Marrow Microenvironment. Blood. 2021 Nov 5; 138(Supplement 1):2236-2236. Ferng FT, Tarver TT, Kabir KS, Braun BB, Logan LA, Gilbert GL, Smith SC. .
      View in: Publisher Site   Mentions:
    16. Allosteric SHP2 Inhibitor RMC4550 Synergizes with Venetoclax in FLT3 and KIT Mutant Acute Myeloid Leukemia. Blood. 2021 Nov 5; 138(Supplement 1):2231-2231. Popescu PB, Stahlhut SC, Tarver TT, Ferng FT, Peretz PC, Wishner WS, Phojanakong PP, Steri SV, Wong WE, Rivera RJ, Stieglitz SE, Smith SC. .
      View in: Publisher Site   Mentions:
    17. Single Cell Sequencing of Pediatric Acute Myeloid Leukemia Reveals Clonal Evolution to Relapse on Combination Chemotherapy with Sorafenib. Blood. 2021 Nov 5; 138(Supplement 1):3470-3470. Peretz PC, Kennedy KV, Ries RR, Meshinchi MS, Smith SC. .
      View in: Publisher Site   Mentions:
    18. Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia. Blood. 2021 Nov 5; 138(Supplement 1):691-691. Daver DN, Perl PA, Maly MJ, Levis LM, Ritchie RE, Litzow LM, McCloskey MJ, Smith SC, Schiller SG, Bradley BT, Tiu TR, Naqvi NK, Dail DM, Siddani SS, Wang WJ, Chyla CB, Lee LP, Altman AJ. .
      View in: Publisher Site   Mentions:
    19. Being Present-CML: A Distress Reduction Intervention for Patients with Chronic Myeloid Leukemia Taking Tyrosine Kinase Inhibitors. Blood. 2021 Nov 5; 138(Supplement 1):4051-4051. Schoenbeck SK, Dhruva DA, Lee LA, Goyal GN, Yang YA, Park PS, Smith SC, Shah SN, Atreya AC. .
      View in: Publisher Site   Mentions:
    20. Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clin Pharmacokinet. 2021 Sep; 60(9):1251. James AJ, Smith CC, Litzow M, Perl AE, Altman JK, Shepard D, Kadokura T, Souda K, Patton M, Lu Z, Liu C, Moy S, Levis MJ, Bahceci E. PMID: 34297319; PMCID: PMC8416867.
      View in: PubMed   Mentions:    Fields:    
    21. AML-162: Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Updated Analyses of a Phase 1b Study. Clinical Lymphoma Myeloma & Leukemia. 2021 Sep 1; 21:s285. Altman AJ, Daver DN, Maly MJ, Levis LM, Ritchie RE, Litzow LM, McCloskey MJ, Smith SC, Schiller SG, Bradley BT, Tiu TR, Naqvi NK, Siddani SS, Wang WJ, Lee LP, Perl PA. .
      View in: Publisher Site   Mentions:
    22. Poster: AML-091: Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib. Clinical Lymphoma Myeloma & Leukemia. 2021 Sep 1; 21:s210. Perl PA, Altman AJ, Hosono HN, Montesinos MP, Podoltsev PN, Martinelli MG, Smith SC, Levis LM, Röllig RC, Groß-Langenhoff GM, Hasabou HN, Lu LQ, Tiu TR. .
      View in: Publisher Site   Mentions:
    23. AML-091: Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib. Clinical Lymphoma Myeloma & Leukemia. 2021 Sep 1; 21:s280. Perl PA, Altman AJ, Hosono HN, Montesinos MP, Podoltsev PN, Martinelli MG, Smith SC, Levis LM, Röllig RC, Groß-Langenhoff GM, Hasabou HN, Lu LQ, Tiu TR. .
      View in: Publisher Site   Mentions:
    24. Poster: AML-162: Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Updated Analyses of a Phase 1b Study. Clinical Lymphoma Myeloma & Leukemia. 2021 Sep 1; 21:s212. Altman AJ, Daver DN, Maly MJ, Levis LM, Ritchie RE, Litzow LM, McCloskey MJ, Smith SC, Schiller SG, Bradley BT, Tiu TR, Naqvi NK, Siddani SS, Wang WJ, Lee LP, Perl PA. .
      View in: Publisher Site   Mentions:
    25. The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment. Haematologica. 2021 08 01; 106(8):2242-2245. Tran TH, Nguyen JV, Stecula A, Akutagawa J, Moorman AV, Braun BS, Sali A, Mullighan CG, Shah NP, Dai Y, Devidas M, Roberts KG, Smith CC, Loh ML. PMID: 33626861; PMCID: PMC8327742.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    26. Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Clin Cancer Res. 2021 07 15; 27(14):4003-4011. Smith CC, Viny AD, Massi E, Kandoth C, Socci ND, Rapaport F, Najm M, Medina-Martinez JS, Papaemmanuil E, Tarver TC, Hsu HH, Le MH, West B, Bollag G, Taylor BS, Levine RL, Shah NP. PMID: 34103301; PMCID: PMC8282743.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    27. Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):7008-7008. Levis LM, Smith SC, Perl PA, Schiller SG, Fathi FA, Roboz RG, Wang WE, Altman AJ, Ando AM, Suzuki ST, Subach SR, Maier MG, Madden MT, Johansen JM, Cheung CK, Kurman KM. .
      View in: Publisher Site   Mentions:
    28. Joint profiling of DNA and proteins in single cells to dissect genotype-phenotype associations in leukemia. Nat Commun. 2021 03 11; 12(1):1583. Demaree B, Delley CL, Vasudevan HN, Peretz CAC, Ruff D, Smith CC, Abate AR. PMID: 33707421; PMCID: PMC7952600.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    29. Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib. Blood Adv. 2021 03 09; 5(5):1437-1441. Peretz CAC, McGary LHF, Kumar T, Jackson H, Jacob J, Durruthy-Durruthy R, Levis MJ, Perl A, Huang BJ, Smith CC. PMID: 33666651; PMCID: PMC7948271.
      View in: PubMed   Mentions: 8     Fields:    
    30. FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies. Front Oncol. 2020; 10:612880. Kennedy VE, Smith CC. PMID: 33425766; PMCID: PMC7787101.
      View in: PubMed   Mentions: 43  
    31. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 12 19; 396(10267):1979-1993. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA, Colin-Jones R, Dold C, Emary KRW, Fedosyuk S, Fuskova M, Gbesemete D, Green C, Hallis B, Hou MM, Jenkin D, Joe CCD, Kelly EJ, Kerridge S, Lawrie AM, Lelliott A, Lwin MN, Makinson R, Marchevsky NG, Mujadidi Y, Munro APS, Pacurar M, Plested E, Rand J, Rawlinson T, Rhead S, Robinson H, Ritchie AJ, Ross-Russell AL, Saich S, Singh N, Smith CC, Snape MD, Song R, Tarrant R, Themistocleous Y, Thomas KM, Villafana TL, Warren SC, Watson MEE, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Faust SN, Pollard AJ, Oxford COVID Vaccine Trial Group. PMID: 33220855; PMCID: PMC7674972.
      View in: PubMed   Mentions: 730     Fields:    Translation:HumansCellsCTClinical Trials
    32. Cognitive Dysfunction Associated with Tyrosine Kinase Inhibitors in Patients with CML in Chronic Phase. Blood. 2020 Nov 5; 136(Supplement 1):2-3. Schoenbeck SK, Tummala TS, Goyal GN, Smith SC, Shah SN. .
      View in: Publisher Site   Mentions:
    33. Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study. Blood. 2020 Nov 5; 136(Supplement 1):20-22. Daver DN, Altman AJ, Maly MJ, Levis LM, Ritchie RE, Litzow LM, McCloskey MJ, Smith SC, Schiller SG, Bradley BT, Tiu TR, Hong HW, Tong TB, Qin QQ, Dilley DK, Perl PA. .
      View in: Publisher Site   Mentions:
    34. Excellent Outcomes Achieved with Medical Management of Chronic Phase CML Patients with Non-Hematologic TKI Intolerance. Blood. 2020 Nov 5; 136(Supplement 1):41-42. Schoenbeck SK, Tummala TS, Olin OR, Goyal GN, Dhruva DA, Damon DL, Logan LA, Smith SC, Shah SN. .
      View in: Publisher Site   Mentions:
    35. Concurrent FLT3 Inhibitor and IDH Inhibitor Therapy in Patients with Acute Myeloid Leukemia (AML). Blood. 2020 Nov 5; 136(Supplement 1):11-12. Fathi FA, Perl PA, Levis LM, Smith SC, Brunner BA, Takahashi TK, Amrein AP, Hock HH, Hobbs HG, Narayan NR, Moran MJ, Bergeron BM, Foster FJ, Daver DN, DiNardo DC. .
      View in: Publisher Site   Mentions:
    36. Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib. Blood. 2020 Nov 5; 136(Supplement 1):22-23. Perl PA, Altman AJ, Hosono HN, Montesinos MP, Podoltsev PN, Martinelli MG, Smith SC, Levis LM, Röllig RC, Groß-Langenhoff GM, Hasabou HN, Lu LQ, Tiu TR. .
      View in: Publisher Site   Mentions:
    37. Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clin Pharmacokinet. 2020 10; 59(10):1273-1290. James AJ, Smith CC, Litzow M, Perl AE, Altman JK, Shepard D, Kadokura T, Souda K, Patton M, Lu Z, Liu C, Moy S, Levis MJ, Bahceci E. PMID: 32304015; PMCID: PMC7550323.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    38. FLT3 Inhibition in Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2020 09; 20 Suppl 1:S5-S6. Smith CC. PMID: 32862867.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    39. A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1711-1721. Smith CC, Levis MJ, Frankfurt O, Pagel JM, Roboz GJ, Stone RM, Wang ES, Severson PL, West BL, Le MH, Kayser S, Lam B, Hsu HH, Zhang C, Bollag G, Perl AE. PMID: 32330242; PMCID: PMC7189289.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    40. Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations. Blood Adv. 2020 02 11; 4(3):514-524. Tarver TC, Hill JE, Rahmat L, Perl AE, Bahceci E, Mori K, Smith CC. PMID: 32040554; PMCID: PMC7013266.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    41. The growing landscape of FLT3 inhibition in AML. Hematology Am Soc Hematol Educ Program. 2019 12 06; 2019(1):539-547. Smith CC. PMID: 31808872; PMCID: PMC6913436.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    42. Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial. Blood. 2019 Nov 13; 134(Supplement_1):14-14. Smith SC, Levis LM, Perl PA, Martinelli MG, Neubauer NA, Berman BE, Montesinos MP, Baer BM, Larson LR, Chou CW, Yokoyama YH, Recher RC, Yoon YS, Hill HJ, Rosales RM, Bahceci BE. .
      View in: Publisher Site   Mentions:
    43. Combined Single-Cell DNA Genotyping and Protein Quantification (DAb-seq) in Acute Myeloid Leukemias Reveals Distinct Immunophenotypic Subsets Among Pathogenic Clones. Blood. 2019 Nov 13; 134(Supplement_1):2088-2088. Demaree DB, Delley DC, Peretz PC, Vasudevan VH, Ruff RD, Ooi OA, Smith SC, Abate AA. .
      View in: Publisher Site   Mentions:
    44. Single Cell Sequencing Reveals Evolution of Tumor Heterogeneity of Acute Myeloid Leukemia on Quizartinib. Blood. 2019 Nov 13; 134(Supplement_1):1440-1440. Cohler Peretz CC, McGary ML, Kumar KT, Jackson JJ, Jacob JJ, Durruthy-Durruthy DR, Zhang ZC, Levis LM, Perl PA, Leung LA, Smith SC. .
      View in: Publisher Site   Mentions:
    45. Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms. Blood. 2019 Nov 13; 134(Supplement_1):1165-1165. Schoenbeck SK, Salmasi SG, Cerejo CM, Cornett CP, Damon DL, Logan LA, Olin OR, Leavitt LA, Smith SC. .
      View in: Publisher Site   Mentions:
    46. Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution. Blood. 2019 Nov 13; 134(Supplement_1):5859-5859. Schoenbeck SK, Cerejo CM, Cornett CP, Damon DL, Gaensler GK, Leavitt LA, Logan LA, Mannis MG, Olin OR, Salmasi SG, Sayre SP, Shah SN, Dhruva DA, Atreya AC, Smith SC. .
      View in: Publisher Site   Mentions:
    47. Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. Blood. 2019 Nov 13; 134(Supplement_1):5089-5089. Mittal MV, Lo LM, Damon DL, Gaensler GK, Martin MT, Olin OR, Smith SC, Logan LA. .
      View in: Publisher Site   Mentions:
    48. Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing. Leukemia. 2020 02; 34(2):662-666. Chao AK, Meyer JA, Lee AG, Hecht A, Tarver T, Van Ziffle J, Koegel AK, Golden C, Braun BS, Sweet-Cordero EA, Smith CC, Dvorak CC, Loh ML, Stieglitz E. PMID: 31511612; PMCID: PMC6995757.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    49. Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients. Biol Blood Marrow Transplant. 2020 01; 26(1):189-196. Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Steinman MA, Huang CY, Olin RL. PMID: 31493541; PMCID: PMC6942208.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    50. Use of FLT3 Inhibitors in AML. Clinical Lymphoma Myeloma & Leukemia. 2019 Sep 1; 19:s92-s94. Smith SC. .
      View in: Publisher Site   Mentions:
    51. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Cancer Discov. 2019 08; 9(8):1050-1063. McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, Pellegrino M, Durruthy-Durruthy R, Watt CD, Asthana S, Lasater EA, DeFilippis R, Peretz CAC, McGary LHF, Deihimi S, Logan AC, Luger SM, Shah NP, Carroll M, Smith CC, Perl AE. PMID: 31088841.
      View in: PubMed   Mentions: 156     Fields:    Translation:HumansCells
    52. Roman warfare: targeting of support cells in AML. Blood. 2019 02 07; 133(6):506-507. Smith CC. PMID: 30733203.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    53. Longitudinal Monitoring of AML Tumors with High-Throughput Single-Cell DNA Sequencing Reveals Rare Clones Prognostic for Disease Progression and Therapy Response. Blood. 2018 Nov 29; 132(Supplement 1):1476-1476. Eastburn ED, McMahon MC, Durruthy-Durruthy DR, Carroll CM, Smith SC, Perl PA. .
      View in: Publisher Site   Mentions:
    54. Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations. Blood. 2018 Nov 29; 132(Supplement 1):1458-1458. Levis LM, Perl PA, Altman AJ, Cortes CJ, Smith SC, Baer BM, Claxton CD, Jurcic JJ, Ritchie RE, Strickland SS, Tibes TR, Hill HJ, Rosales RM, Bahceci BE. .
      View in: Publisher Site   Mentions:
    55. Functional Status Is Associated with Outcomes after Allogeneic Stem Cell Transplantation for Older Patients with Hematologic Malignancies. Blood. 2018 Nov 29; 132(Supplement 1):3599-3599. Huang HL, Huang HC, Andreadis AC, Logan LA, Mannis MG, Smith SC, Gaensler GK, Martin MT, Damon DL, Steinman SM, Olin OR. .
      View in: Publisher Site   Mentions:
    56. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018 07; 19(7):889-903. Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M. PMID: 29859851; PMCID: PMC8152787.
      View in: PubMed   Mentions: 123     Fields:    Translation:HumansCTClinical Trials
    57. Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with FLT3 -ITD–mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment. Journal of Clinical Oncology. 2018 May 20; 36(15_suppl):7017-7017. Levis LM, Smith SC, Ishizuka IK, Kobayashi KK, Arunachalam AM, Wang WY, Lazzaretto LD, Cortes CJ. .
      View in: Publisher Site   Mentions:
    58. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017 08; 18(8):1061-1075. Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M. PMID: 28645776; PMCID: PMC5572576.
      View in: PubMed   Mentions: 226     Fields:    Translation:HumansCellsCTClinical Trials
    59. Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. Journal of Clinical Oncology. 2017 May 20; 35(15_suppl):7003-7003. Altman AJ, Perl PA, Cortes CJ, Smith SC, Litzow LM, Hill HJ, Larson LR, Liu LC, Ritchie RE, Strickland SS, Wang WE, Neubauer NA, Martinelli MG, Bahceci BE, Levis LM. .
      View in: Publisher Site   Mentions:
    60. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood. 2017 07 06; 130(1):48-58. Smith CC, Paguirigan A, Jeschke GR, Lin KC, Massi E, Tarver T, Chin CS, Asthana S, Olshen A, Travers KJ, Wang S, Levis MJ, Perl AE, Radich JP, Shah NP. PMID: 28490572; PMCID: PMC5501146.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansCTClinical Trials
    61. Pharmacokinetics and pharmacodynamics of gilteritinib in patients with relapsed or refractory acute myeloid leukemia. Journal of Clinical Oncology. 2016 May 20; 34(15_suppl):7026-7026. Smith SC, Levis LM, Litzow LM, Perl PA, Altman AJ, Gill GS, Yuen YG, Bonate BP, Kadokura KT, James JA, Liu LC, Nagase NI, Fisniku FO, Bahceci BE. .
      View in: Publisher Site   Mentions:
    62. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar; 1(3):e85630. Minson KA, Smith CC, DeRyckere D, Libbrecht C, Lee-Sherick AB, Huey MG, Lasater EA, Kirkpatrick GD, Stashko MA, Zhang W, Jordan CT, Kireev D, Wang X, Frye SV, Earp HS, Shah NP, Graham DK. PMID: 27158668; PMCID: PMC4855528.
      View in: PubMed   Mentions: 34     Fields:    
    63. Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. Leuk Lymphoma. 2016 07; 57(7):1560-6. Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C. PMID: 26490487.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    64. Resistance to FLT3 Inhibitors. Resistance to Tyrosine Kinase Inhibitors. 2016 Jan 1; 131-145. Ferng FT, Smith SC. .
      View in: Publisher Site   Mentions:
    65. Pharmacokinetic Profile and Pharmacodynamic Effects of ASP2215, a Selective, Potent Inhibitor of FLT3/AXL, in Patients with Relapsed or Refractory Acute Myeloid Leukemia: Results from a First-in-Human Phase 1/2 Study. Blood. 2015 Dec 3; 126(23):4836-4836. Smith SC, Levis LM, Litzow LM, Perl PA, Altman AJ, Gill GS, Kadokura KT, Yuen YG, Fisniku FO, Liu LC, Nagase NI, Sargent SB, Welter WN, Bahceci BE. .
      View in: Publisher Site   Mentions:
    66. Recurrent Mutations in CCND3 Confer Clinical Resistance to FLT3 Inhibitors. Blood. 2015 Dec 3; 126(23):677-677. Smith SC, Viny VA, Massi ME, Kandoth KC, Socci SN, Hsu HH, West WB, Bollag BG, Taylor TB, Levine LR, Shah SN. .
      View in: Publisher Site   Mentions:
    67. Identifying Drug-Resistant Mutations in Ebf1-Pdgfrb Ph-like Acute Lymphoblastic Leukemia. Blood. 2015 Dec 3; 126(23):1423-1423. Tran TT, Nguyen NJ, Smith SC, Roberts RK, Mullighan MC, Shah SN, Loh LM. .
      View in: Publisher Site   Mentions:
    68. Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). Journal of Clinical Oncology. 2015 May 20; 33(15_suppl):7003-7003. Levis LM, Perl PA, Altman AJ, Cortes CJ, Ritchie RE, Larson LR, Smith SC, Wang WE, Strickland SS, Baer BM, Litzow LM, Claxton CD, Schiller SG, Ustun UC, Liu LC, Gill GS, Sargent SB, Bahceci BE. .
      View in: Publisher Site   Mentions:
    69. Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397. Cancer Discov. 2015 Jun; 5(6):668-79. Smith CC, Zhang C, Lin KC, Lasater EA, Zhang Y, Massi E, Damon LE, Pendleton M, Bashir A, Sebra R, Perl A, Kasarskis A, Shellooe R, Tsang G, Carias H, Powell B, Burton EA, Matusow B, Zhang J, Spevak W, Ibrahim PN, Le MH, Hsu HH, Habets G, West BL, Bollag G, Shah NP. PMID: 25847190; PMCID: PMC4522415.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansAnimalsCells
    70. Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors. Eur J Med Chem. 2015 Apr 13; 94:123-31. Frett B, McConnell N, Smith CC, Wang Y, Shah NP, Li HY. PMID: 25765758; PMCID: PMC4666306.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    71. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):377-83. Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG. PMID: 25776193.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    72. Long-Term Outcomes of 133 Patients with Intermediate-Risk Acute Myeloid Leukemia Treated with High-Dose Chemotherapy and Autologous Stem Cell Rescue in First Complete Remission. Biology of Blood and Marrow Transplantation. 2015 Feb 1; 21(2):s141-s142. Mannis MG, Martin MT, Damon DL, Logan LA, Ai AW, Gaensler GK, Kaplan KL, Mahindra MA, Olin OR, Sayre SP, Smith SC, Wolf WJ, Hwang HJ, Andreadis AC. .
      View in: Publisher Site   Mentions:
    73. Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. Elife. 2014 Dec 22; 3. Warkentin AA, Lopez MS, Lasater EA, Lin K, He BL, Leung AY, Smith CC, Shah NP, Shokat KM. PMID: 25531068; PMCID: PMC4307180.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    74. MRX2843, a Novel Dual MerTK-FLT3 Inhibitor with Activity Against Resistance-Conferring FLT3 Mutations in Acute Myeloid Leukemia. Blood. 2014 Dec 6; 124(21):3757-3757. Minson MK, Smith SC, Lee-Sherick LA, DeRyckere DD, Lasater LE, Hill HA, Wang WX, Frye FS, Earp EH, Shah SN, Graham GD. .
      View in: Publisher Site   Mentions:
    75. Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. Cell Rep. 2014 Nov 20; 9(4):1333-48. Chatterjee A, Ghosh J, Ramdas B, Mali RS, Martin H, Kobayashi M, Vemula S, Canela VH, Waskow ER, Visconte V, Tiu RV, Smith CC, Shah N, Bunting KD, Boswell HS, Liu Y, Chan RJ, Kapur R. PMID: 25456130; PMCID: PMC4380442.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimalsCells
    76. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. PMID: 24894413.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    77. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep. 2014 Jun; 9(2):174-85. Sudhindra A, Smith CC. PMID: 24682858.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    78. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A. 2014 Apr 08; 111(14):5319-24. Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK, Damon LE, Perl AE, Jeschke GR, Sugita M, Carroll M, Kogan SC, Kuriyan J, Shah NP. PMID: 24623852; PMCID: PMC3986131.
      View in: PubMed   Mentions: 98     Fields:    Translation:HumansCells
    79. Comprehensive Geriatric Assessment Identifies Significant Functional Impairments in Older Hematopoietic Cell Transplant Recipients. Biology of Blood and Marrow Transplantation. 2014 Feb 1; 20(2):s65-s66. Olin OR, Andreadis AC, Martin MT, Wolf WJ, Kaplan KL, Ai AW, Venstrom VJ, Logan LA, Smith SC, Gaensler GK, Hwang HJ, Damon DL. .
      View in: Publisher Site   Mentions:
    80. A Phase 1 Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination with Etoposide As Preparative Therapy for Autologous Stem Cell Transplant in Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation. 2014 Feb 1; 20(2):s114-s115. Mannis MG, Damon DL, Ai AW, Andreadis AC, Gaensler GK, Kaplan KL, Logan LA, Mahindra MA, Olin OR, Sayre SP, Smith SC, Venstrom VJ, Wolf WJ, Martin MT. .
      View in: Publisher Site   Mentions:
    81. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res. 2014 Mar; 38(3):316-22. Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP. PMID: 24374145; PMCID: PMC4414320.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    82. Disease diversity and FLT3 mutations. Proc Natl Acad Sci U S A. 2013 Dec 24; 110(52):20860-1. Smith CC. PMID: 24324154; PMCID: PMC3876196.
      View in: PubMed   Mentions: 5     Fields:    Translation:Animals
    83. Delayed Hematopoietic Recovery After Autologous Stem Cell Transplantation In Patients Receiving Arsenic Trioxide-Based Therapy For Acute Promyelocytic Leukemia. Blood. 2013 Nov 15; 122(21):2172-2172. Mannis MG, Damon DL, Ai AW, Andreadis AC, Gaensler GK, Gupta GN, Kaplan KL, Leavitt LA, Logan LA, Olin OR, Sayre SP, Smith SC, Venstrom VJ, Martin MT. .
      View in: Publisher Site   Mentions:
    84. Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML). Blood. 2013 Nov 15; 122(21):3938-3938. Smith SC, Lin LK, Lasater LE, Stewart SW, Damon DL, Kasarskis KA, Bashir BA, Pendleton PM, Sebra SR, Perl PA, Le LM, Zhang ZC, West WB, Shah SN. .
      View in: Publisher Site   Mentions:
    85. Mutations At The FLT3 Activation Loop D835 Residue Confer Differential Resistance To Clinically Active FLT3 Inhibitors. Blood. 2013 Nov 15; 122(21):3929-3929. Lin LK, Smith SC, Salerno SS, Shah SN. .
      View in: Publisher Site   Mentions:
    86. Association of age-dependent liver injury and fibrosis with immune cell populations. Liver Int. 2013 Sep; 33(8):1175-86. Collins BH, Holzknecht ZE, Lynn KA, Sempowski GD, Smith CC, Liu S, Parker W, Rockey DC. PMID: 23710620; PMCID: PMC4151465.
      View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells
    87. The Role of Kinase Inhibitors in the Treatment of Patients with Acute Myeloid Leukemia. American Society of Clinical Oncology Educational Book. 2013 May 1; (33):313-318. Smith SC, Shah SN. .
      View in: Publisher Site   Mentions:
    88. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood. 2013 Apr 18; 121(16):3165-71. Smith CC, Lasater EA, Zhu X, Lin KC, Stewart WK, Damon LE, Salerno S, Shah NP. PMID: 23430109; PMCID: PMC3630831.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCells
    89. Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Is Predictive of Serious Adverse Events and Overall Survival in Older Allogeneic Transplant Recipients. Biology of Blood and Marrow Transplantation. 2013 Feb 1; 19(2):s293-s294. Keller KJ, Damon DL, Kaplan KL, Martin MT, Wolf WJ, Ai AW, Andreadis AC, Venstrom VJ, Smith SC, Gaensler GK, Hwang HJ, Olin OR. .
      View in: Publisher Site   Mentions:
    90. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2013; 313-8. Smith CC, Shah NP. PMID: 23714533.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    91. Single-Cell Pharmacodynamic Monitoring of Ribosomal Protein S6 Phosphorylation During AC220 Therapy Demonstrates in Vivo FLT3 Inhibition in Circulating Leukemic Blasts and Accurately Detects the Development of AC220 Resistance. Blood. 2012 Nov 16; 120(21):2453-2453. Perl PA, Jeschke JG, Smith SC, Mangan MJ, Luger LS, Carroll CM. .
      View in: Publisher Site   Mentions:
    92. Competitive Allele Specific TaqMan® PCR (castPCR™) Technology for Sensitive Detection of AC220-Resistant FLT3 Kinase Domain Mutations in Primary AML Patient Samples. Blood. 2012 Nov 16; 120(21):2559-2559. Cheng CW, Lasater LE, Smith SC, Mokang MM, Bao BY, Shah SN. .
      View in: Publisher Site   Mentions:
    93. Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220. Blood. 2012 Nov 16; 120(21):674-674. Smith SC, Chin CJ, Lasater LE, Paguirigan PA, Lin LK, Stewart SW, Salerno SS, Damon DL, Levis LM, Perl PA, Travers TK, Kasarskis KA, Radich RJ, Shah SN. .
      View in: Publisher Site   Mentions:
    94. Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects the Evolution of Polyclonal and Compound BCR-ABL Mutations in Patients Who Relapse On Kinase Inhibitor Therapy. Blood. 2012 Nov 16; 120(21):917-917. Smith SC, Brown BM, Parker PW, Lin LK, Travers TK, Wang WS, Branford BS, Shah SN. .
      View in: Publisher Site   Mentions:
    95. Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants. Blood. 2012 Nov 16; 120(21):141-141. Smith SC, Lasater LE, Mccreery MM, Lin LK, Stewart SW, Damon DL, Perl PA, Jeschke JG, Sugita SM, Carroll CM, Kogan KS, Shah SN. .
      View in: Publisher Site   Mentions:
    96. Mechanisms of Resistance to Targeted Therapies in Acute Myeloid Leukemia and Chronic Myeloid Leukemia. American Society of Clinical Oncology Educational Book. 2012 Jun 1; (32):685-689. Smith SC, Shah SN. .
      View in: Publisher Site   Mentions:
    97. Abstract 1893: Activating NRAS mutations are associated with FLT3-independent resistance to the clinically active FLT3 inhibitor AC220 in vitro. Experimental and Molecular Therapeutics. 2012 Apr 15; 1893-1893. Lasater LE, Smith SC, Shah SN. .
      View in: Publisher Site   Mentions:
    98. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012 Apr 15; 485(7397):260-3. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP. PMID: 22504184; PMCID: PMC3390926.
      View in: PubMed   Mentions: 358     Fields:    Translation:HumansCells
    99. Mechanisms of resistance to targeted therapies in acute myeloid leukemia and chronic myeloid leukemia. Am Soc Clin Oncol Educ Book. 2012; 685-9. Smith CC, Shah NP. PMID: 24451819.
      View in: PubMed   Mentions:    Fields:    
    100. Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects Polyclonal and Compound BCR-ABL in Patients Who Relapse on Kinase Inhibitor Therapy,. Blood. 2011 Nov 18; 118(21):3752-3752. Smith SC, Brown BM, Chin CJ, Kasap KC, Salerno SS, Damon DL, Travers TK, Wang WS, Kasarskis KA, Schadt SE, Shah SN. .
      View in: Publisher Site   Mentions:
    101. PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro. Blood. 2011 Nov 18; 118(21):764-764. Smith SC, Perl PA, Lasater LE, Zhang ZC, Jeschke JG, Damon DL, Carroll CM, Shah SN. .
      View in: Publisher Site   Mentions:
    102. Phospho-Specific Flow Cytometry of Fixed Whole Blood Demonstrates In Vivo FLT3 Inhibition in Circulating Leukemic Blasts During AC220 Therapy and Accurately Detects the Development of Therapeutic Resistance,. Blood. 2011 Nov 18; 118(21):3502-3502. Perl PA, Jeschke JG, Smith SC, Mangan MJ, Luger LS, Carroll CM. .
      View in: Publisher Site   Mentions:
    103. Validation of FLT3-ITD As a Therapeutic Target in Human Acute Myeloid Leukemia. Blood. 2011 Nov 18; 118(21):937-937. Smith SC, Chin CJ, Wang WQ, Salerno SS, Damon DL, Hunt HJ, Levis LM, Perl PA, Travers TK, Wang WS, Kasarskis KA, Schadt SE, Kuriyan KJ, Shah SN. .
      View in: Publisher Site   Mentions:
    104. A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results. Blood. 2011 Nov 18; 118(21):2576-2576. Cortes CJ, Perl PA, Smith SC, Kovacsovics KT, Dombret DH, Dohner DH, Steffen SB, Pigneux PA, Rousselot RP, Krauter KJ, Martinelli MG, Estey EE, Burnett BA, Ho HA, Ifrah IN, de Witt dT, Corringham CR, James JJ, Lilienfeld LD, Leo LE, Gammon GG, Levis LM. .
      View in: Publisher Site   Mentions:
    105. Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3 Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD Mutants. Blood. 2011 Nov 18; 118(21):930-930. Smith SC, Damon DL, Zhu ZX, Salerno SS, Shah SN. .
      View in: Publisher Site   Mentions:
    106. Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations. Blood. 2011 Nov 18; 118(21):2611-2611. Fiskus FW, Smith SC, Smith SJ, Wise WS, Lasater LE, Damon DL, Salerno SS, Fleming FA, Reyes RR, Ganguly GS, Berger BM, Rutkoski RT, McGuirk MJ, Shah SN, Bhalla BK. .
      View in: Publisher Site   Mentions:
    107. Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia. Clin Cancer Res. 2011 Nov 01; 17(21):6605-7. Smith CC, Shah NP. PMID: 21948230.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    108. Abstract 4737: Saturation mutagenesis of FLT3-ITD: AC220-resistance-conferring kinase domain mutations are restricted to a limited number of residues and are cross-resistant to sorafenib in vitro. Experimental and Molecular Therapeutics. 2011 Apr 15; 4737-4737. Smith SC, Damon DL, Salerno SS, Shah SN. .
      View in: Publisher Site   Mentions:
    109. Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease. Hematology Am Soc Hematol Educ Program. 2011; 2011:121-7. Smith CC, Shah NP. PMID: 22160023.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    110. Cost-effectiveness of private umbilical cord blood banking. Obstet Gynecol. 2009 Oct; 114(4):848-855. Kaimal AJ, Smith CC, Laros RK, Caughey AB, Cheng YW. PMID: 19888044.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    111. Fluorometric assay for N-acetylprocainamide. Clin Chem. 1975 Dec; 21(13):1899-902. Matusik E, Gibson TP. PMID: 160.
      View in: PubMed   Mentions:
    112. [The analgesic efficacy of pentazocine (fortalgesic winthrop) in suppositories with postoperative pains (author's transl)]. Ther Umsch. 1975 Nov; 32(11):730-5. Rusch G, Chaker RB. PMID: 7026.
      View in: PubMed   Mentions:
    113. Metal substitutions incarbonic anhydrase: a halide ion probe study. Biochem Biophys Res Commun. 1975 Oct 27; 66(4):1281-6. Smith RJ, Bryant RG. PMID: 3.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    With one click, see people who:

    Mentor Faculty

    Offer Student Projects

    Run Clinical Trials

    Work in Global Health Equity

    See more options in the Advanced Search tab

    Catherine's Networks
    Concepts (218)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (52)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-2-gbbe5f151 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.